EKTA.F Stock Overview
A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Elekta AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 5.42 |
| 52 Week High | SEK 8.40 |
| 52 Week Low | SEK 5.42 |
| Beta | 1.12 |
| 11 Month Change | -20.53% |
| 3 Month Change | -19.10% |
| 1 Year Change | -35.09% |
| 33 Year Change | -53.67% |
| 5 Year Change | -55.94% |
| Change since IPO | -58.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| EKTA.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -5.2% | 0.9% | 2.2% |
| 1Y | -35.1% | 21.9% | 32.6% |
Return vs Industry: EKTA.F underperformed the US Medical Equipment industry which returned 21.9% over the past year.
Return vs Market: EKTA.F underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| EKTA.F volatility | |
|---|---|
| EKTA.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EKTA.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine EKTA.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 4,566 | Gustaf Salford | elekta.com |
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software.
Elekta AB (publ) Fundamentals Summary
| EKTA.F fundamental statistics | |
|---|---|
| Market cap | US$2.23b |
| Earnings (TTM) | US$102.95m |
| Revenue (TTM) | US$1.64b |
21.7x
P/E Ratio1.4x
P/S RatioIs EKTA.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKTA.F income statement (TTM) | |
|---|---|
| Revenue | SEK 18.12b |
| Cost of Revenue | SEK 11.49b |
| Gross Profit | SEK 6.63b |
| Other Expenses | SEK 5.50b |
| Earnings | SEK 1.13b |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | 2.97 |
| Gross Margin | 36.60% |
| Net Profit Margin | 6.26% |
| Debt/Equity Ratio | 60.6% |
How did EKTA.F perform over the long term?
See historical performance and comparison